ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.

Laura Q M ChowFabrice BarlesiErin M Bertino Martin J Van Den Bent Heather A WakeleePatrick Y WenChao-Hua ChiuSergey OrlovRita ChiariMargarita Majem TarruellaMark McKeageChong-Jen YuPilar Garrido Lopez Felipe K HurtadoPilar Cazorla ArratiaYuanbo SongFabrice BranleMichael ShiDong Wan Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Ceritinib showed antitumor activity in patients with ALK+ NSCLC with active brain metastases and/or leptomeningeal disease, and could be considered in the management of intracranial disease. See related commentary by Murciano-Goroff et al., p. 2477.

Keyphrases

brain metastases
small cell lung cancer
advanced non small cell lung cancer
squamous cell carcinoma
white matter
resting state
brain injury
replacement therapy
tyrosine kinase
smoking cessation
subarachnoid hemorrhage
drug induced